Proton-Pump Inhibitors (PPI)

Proton-Pump Inhibitors

Proton-Pump Inhibitors (PPls),such Nexium, Prilosec, and now their generic and OTC versions, are some of the most widely prescribed, over-prescribed, and profitable medications ever marketed. For more than 25 years, they were marketed to doctors as completely safe, and they are incredibly effective at preventing simple heartburn, an unapproved indication. As a result, most PPI prescriptions have been for unapproved indications and approved for OTC use.

Despite selling these drugs with no warnings for over two decades, PPls are not risk-free. There are numerous injuries associated with PPI use, including bone fractures, infections, magnesium deficiency, dementia, cancer, Acute Interstitial Nephritis (AIN), Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD), leading to End Stage Renal Disease (ESRD). Starting in 2010, a bone fracture warning was added. In 2011, a magnesium deficiency warning was added. In 2014, an AIN warning was added. Finally, in 2016, multiple studies concluded that PPI’s dramatically increase a person’s risk of kidney failure and kidney disease. However, there is still no warning for CKD and there has never been any warning on OTC PPI products.

The litigation involves product liability claims against the manufacturers of PPls, which include Nexium, Prilosec, Prevacid, Protonix, AcipHex, Zegerid, Dexilant, Vimovo, and their generic and over-the-counter (OTC) counterparts.

The Proton-Pump Inhibitors (PPI) Litigation Group helps members investigate and litigate claims against the manufacturers of PPls. Members of the Group have access to a secure, members-only list server and document library, as well as meeting and education programs throughout the year.

Dues:

$300 annually

Cochairs:

• Tracy Finken Magnotta | Anapol Weiss, Philadelphia, PA
• Paul J. Pennock | Morgan & Morgan, Brooklyn, NY